Literature DB >> 2682942

Infection and cyclosporine.

J H Kim1, J R Perfect.   

Abstract

Cyclosporine is a potent immunosuppressive agent that selectively impairs T cell function. The steady growth of its importance makes knowledge of its activity and effects clinically relevant. The intrinsic antibiotic activity of cyclosporine is limited; although it inhibits certain viruses, fungi, protozoa, and helminths, in practical terms these effects are insignificant. Both controlled and noncontrolled studies have shown that infection is an infrequent problem in patients with autoimmune diseases who are receiving relatively low doses. The use of cyclosporine in the setting of transplantation does not increase--and may in fact decrease--the incidence of infection in comparison with that during standard immunosuppressive therapy. Fungal, viral, and bacterial diseases remain a risk, however, and are a significant cause of morbidity in this population. Antimicrobial therapy may alter cyclosporine levels and cause nephrotoxicity or graft rejection. Careful monitoring of cyclosporine levels during antimicrobial treatment is therefore recommended.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2682942     DOI: 10.1093/clinids/11.5.677

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  19 in total

Review 1.  The cyclosporins.

Authors:  Z Rehácek
Journal:  Folia Microbiol (Praha)       Date:  1995       Impact factor: 2.099

Review 2.  Safety aspects of cyclosporin in rheumatoid arthritis.

Authors:  B A Dijkmans
Journal:  Drugs       Date:  1995       Impact factor: 9.546

Review 3.  Infections in solid-organ transplant recipients.

Authors:  R Patel; C V Paya
Journal:  Clin Microbiol Rev       Date:  1997-01       Impact factor: 26.132

4.  Treatment of Cyclosporin A retains host defense against invasive pulmonary aspergillosis in a non-immunosuppressive murine model by preserving the myeloid cell population.

Authors:  Sarah Sze Wah Wong; Orhan Rasid; Paris Laskaris; Arnaud Fekkar; Jean-Marc Cavaillon; William J Steinbach; Oumaima Ibrahim-Granet
Journal:  Virulence       Date:  2017-07-06       Impact factor: 5.882

5.  Triple drug immunosuppression significantly reduces immune activation and allograft arteriosclerosis in cytomegalovirus-infected rat aortic allografts and induces early latency of viral infection.

Authors:  K B Lemström; J H Bruning; C A Bruggeman; I T Lautenschlager; P J Häyry
Journal:  Am J Pathol       Date:  1994-06       Impact factor: 4.307

Review 6.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

7.  [Bacterial osteitis. Special considerations in immunocompromised patients].

Authors:  C Niedhart; O Miltner; K-W Zilkens; F U Niethard
Journal:  Orthopade       Date:  2004-03       Impact factor: 1.087

8.  Decreased incidence of infection after renal transplantation with the use of cyclosporine.

Authors:  C d'Ivernois; M Dupon; J F Dartigues; L Potaux; M Aparicio; J Y Lacut
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-11       Impact factor: 3.267

Review 9.  Diseases and drug-related interventions affecting host defence.

Authors:  S de Marie
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993       Impact factor: 3.267

10.  Cyclosporin A increases the pulmonary eosinophilia induced by inhaled Aspergillus antigen in mice.

Authors:  J M Wang; M Denis; M Fournier; M Laviolette
Journal:  Clin Exp Immunol       Date:  1993-09       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.